Searchable abstracts of presentations at key conferences in endocrinology

ea0005p173 | Growth and Development | BES2003

The effect of chronic administration of recombinant (human) leptin on the growth performance of neonatal pigs

Litten J , Bell M , Perkins K , Clarke L

Leptin, 16 kDa polypeptide hormone is produced primarily, although not exclusively, by adipocytes. It has been proposed to play a role in neonatal growth and development. The objective of the study was to investigate the effect of chronic leptin administration on the growth performance and endocrine profile of neonatal pigs. Ten Meishan sows gave birth naturally at term and siblings were paired by birth weight and gender. Piglets were subsequently randomly allocated to either ...

ea0026p253 | Pituitary | ECE2011

The value of T2 weighted MR-imaging for stratification to medical therapy in newly diagnosed acromegaly

Heck A , Ringstad G , Casar-Borota O , Fougner S L , Hald J , Ramm-Pettersen J , Bollerslev J

Background: Signal intensity in T2 weighted (w) MRI in somatotroph pituitary adenomas has been described to correlate with histological granulation pattern. Long-term somato-statin analogue (SSA)-response is associated with both histological subtype and T2wMRI.Objective: To describe secretory baseline characteristics in newly diagnosed acromegalic patients in relation to T2 signal intensity. Moreover, to test whether T2 w images could predict preoperativ...

ea0005p171 | Growth and Development | BES2003

The effect of chronic administration of recombinant (human) leptin on leptin and uncoupling protein (UCP) 2 mRNA in neonatal pigs

Litten J , Perkins K , Bell M , Clarke L

Leptin, the 16 kDa product of the obese gene, and uncoupling proteins (UCP) are both involved in energy expenditure. Piglets have recently been shown to express UCP2, it has been speculated that the induction of UCP2 in adipose tissue by leptin may stimulate thermogenesis. The aim of this study was to investigate the effect of leptin administration on body temperature, leptin and UCP2 mRNA. Ten Meishan sows gave birth naturally at term and siblings were paired by birth weight ...

ea0018p31 | (1) | MES2008

Diagnostic cut-off for calcitonin: is 10 ng/l still valid?

Ramachandran Radha , Benfield Patricia , White Sara , Chapman Richard , Meeran Karim , Donaldson Mandy , Martin Niamh

Aim: Population studies have shown that basal calcitonin concentrations are below 10 ng/l in the normal population. Ten nanograms per liter is used as a diagnostic cut-off by most laboratories and patients with levels higher than this are offered a pentagastrin stimulation test to exclude medullary thyroid carcinoma. However, these guidelines were adopted from studies that used the Cisbio Immunoradiometric assay for measuring calcitonin. Most laboratories have now moved to che...

ea0010p29 | Diabetes, metabolism and cardiovascular | SFE2005

Circulating alanine aminotransferase (ALT) is elevated in obese women with PCOS, and is reduced by protracted metformin treatment

Fleming R , Harborne L , Norman J , Sattar N

Serum ALT concentrations give some insight into liver fat accumulation and relate to metabolic syndrome: values >29 IU/L double risk of type 2 diabetes independent of other risk predictors. Women with PCOS are at increased risk of diabetes and CVD whereas metformin treatment modulates the progress of metabolic syndrome. Consequently, we investigated the effects of protracted metformin treatment on circulating ALT in obese women with PCOS.Metformin tr...

ea0012p133 | Thyroid | SFE2006

Does L-thyroxine reduce weight in people with subclinical hypothyroidism?

Razvi S , Pearce SH , Weaver JU

ObjectiveIt is controversial whether subclinical hypothyroidism (SCH) always reflects mild thyroid failure and if treatment is beneficial. The arguments in favour of treatment are prevention of progression, reducing cholesterol levels and improving symptoms. The consequence of SCH on body weight and its response to treatment has never been studied in a systematic manner.MethodsUnselected population-based stud...

ea0056gp111 | Diabetes Translational | ECE2018

Olfactory receptor OR51E1 mediates GLP-1 secretion in enteroendocrine L cells

Ku Cheol Ryong , Han Ye Eon , Kim Daham , Hong Jae Won , Kim Sun Ho , Lee Eun Jig

Few studies have investigated the intracellular signaling pathways mediating the effects of glucagon-like peptide-1 (GLP-1) secretagogues in enteroendocrine L cells. Specific receptors, channels, and intracellular signaling proteins expressed by the L cells have only begun to be characterized. The present study aimed to investigate the role of the olfactory receptor (OR) OR51E1 in GLP-1 secretion. We verified the expression of olfactory marker protein (OMP), an indicator of OR...

ea0083ercp4 | Endocrine-related Cancer | EYES2022

Impact of androgen deprivation therapy on the bone and metabolic changes in men treated for localized prostate cancer

L Tonkic , T Milicevic Milardovic , A Novak , J Nazlic

Background: Prostate cancer is the most commonly diagnosed male malignancy. Androgen Deprivation Therapy (ADT) with GnRH agonist is commonly used intreating localized prostate cancer. Side effect of ADT is a loss of bone density resulting inosteopenia or osteoporosis. Research concerningpossible molecular and cellular mechanisms of ADT-induced bone changes are still incomplete. Matrix Gla Protein (MGP) is a vitamin-K-dependent protein which is synthesized in a variety of tissu...

ea0010dp8 | Diabetes, metabolism and cardiovascular | SFE2005

Circulating alanine aminotransferase (ALT) is elevated in obese women with PCOS, and is reduced by protracted metformin treatment

Fleming R , Harborne L , Norman a J , Sattar N

Serum ALT concentrations give some insight into liver fat accumulation and relate to metabolic syndrome: values>29 IU/L double risk of type 2 diabetes independent of other risk predictors. Women with PCOS are at increased risk of diabetes and CVD whereas metformin treatment modulates the progress of metabolic syndrome. Consequently, we investigated the effects of protracted metformin treatment on circulating ALT in obese women with PCOS.Methods<p...

ea0019p269 | Pituitary | SFEBES2009

The management of microprolactinoma: are we following the guidelines for dopamine agonist withdrawal?

Huda M , Wee J , Kwok H , Lawrence U , Moore R , Scally L , Gibbs C , Tremble J

Background: Dopamine agonist (DA) withdrawal is common in the management of microprolactinoma. Guidelines in 19971 and 20062 suggest that DA should be withdrawn after normoprolactinaemia for 3 years.Aims: To assess DA withdrawal and adherence to guidelines.Methods: We retrospectively examined casenotes from 1997 to 2008. Patients were included with clinical and biochemical evidence of hyperprolactinaemia, and ...